Hepatic Encephalopathy (HE) - Management

Pathophysiology (Brief)

• Ammonia accumulation - produced in the colon by bacterial metabolism of protein/nitrogen compounds; normally cleared by hepatocytes but diverted via portosystemic shunting in cirrhosis
• Blood-brain barrier disruption - increases ammonia extraction by cerebellum and basal ganglia, causing astrocyte swelling, brain edema, and cytotoxic injury
• Neurotransmitter dysregulation - enhanced GABA/benzodiazepine receptor sensitivity (mediated by astrocyte neurosteroids), altered serotonin, NO, and opioid peptide signaling
• Inflammatory cascade - bacterial translocation and systemic inflammation amplify neurological dysfunction

Classification - West Haven Criteria

Types of HE

Precipitating Factors (ALWAYS identify and treat)

Management Framework

Step 1: Supportive Care

• Resuscitate and correct hemodynamic instability
• IV fluid resuscitation and rehydration
• Correct electrolyte abnormalities (especially hypokalemia, alkalosis)
• Ensure adequate caloric intake
• Airway protection in Grade 3-4 (intubation if needed)
• Avoid hepatotoxic and CNS-depressant drugs

Step 2: Reduce Gut Ammonia - Pharmacotherapy

First-Line: Lactulose

• Mechanism: Non-absorbable disaccharide; acts as cathartic to purge nitrogenous waste; acidifies colon (traps NH₃ as NH₄⁺, non-absorbable); reduces urease-producing bacteria
• Dose: 15-45 mL PO bid-qid (or 30 mL every 1-2 hours in acute phase, then taper once bowel movements begin)
• Target: 2-3 soft stools per day (titrate dose to achieve this)
• Enema: 300 mL lactulose + 700 mL distilled water for patients unable to take oral intake
• Cautions: Avoid in ileus or bowel obstruction; monitor for hypovolemia and hypernatremia
• Washington Manual, p.748; Goldman-Cecil Medicine; Symptom to Diagnosis

Second-Line / Add-on: Rifaximin

• Mechanism: Oral non-absorbable broad-spectrum antibiotic; reduces intestinal bacterial load and urease activity
• Dose: 550 mg PO bid (some sources cite 400 mg every 8 hours for acute phase)
• Evidence: RCT showed rifaximin + lactulose reduces recurrence of HE and time to first hospitalization over 6 months (49.1% reduction vs. lactulose alone + placebo)
• Role: Add rifaximin in patients not improving on lactulose alone; preferred over neomycin due to better safety profile
• Secondary prophylaxis: Rifaximin + lactulose for patients with recurrent encephalopathy
• Washington Manual; Mulholland and Greenfield's Surgery, p.2893

Alternative Antibiotics (less preferred)

• Neomycin: 500 mg to 1 g PO tid - limited by ototoxicity and nephrotoxicity
• Metronidazole: 250 mg PO bid-qid - limited by neurotoxicity with prolonged use

Step 3: Bowel Decontamination

• Bowel purge with oral cathartics or enemas to remove blood and nitrogenous compounds (especially after GI bleeding)
• Polyethylene glycol (PEG) 3350-electrolyte solution (4 L PO/NG over 4 hours) may produce more rapid clinical response than lactulose alone - Goldman-Cecil Medicine

Step 4: Nutrition

• Do NOT restrict dietary protein chronically - this worsens sarcopenia and malnutrition in cirrhosis, which independently worsens prognosis
• Target 1.2-1.5 g/kg/day protein intake
• Switch from animal protein to vegetable/dairy protein in recurrent/persistent HE (reduces ammoniagenic amino acids)
• Branched-chain amino acids (BCAAs): Supplement in patients intolerant of protein; corrects the BCAA:aromatic amino acid imbalance and improves recovery from episodic HE
• L-carnitine: Has been shown to improve cognitive deficits and reduce ammonia levels
• Late evening snack: Recommended by ACG 2025 guidelines to improve lean muscle tissue and reduce HE risk
• Mulholland and Greenfield's Surgery; Rosen's Emergency Medicine

Secondary Prophylaxis (Prevention of Recurrence)

1. Lactulose - continue long-term; may discontinue if precipitating factor is well-controlled and liver/nutritional function has improved
2. Rifaximin + lactulose - for patients with recurrent HE; significantly reduces further recurrence
3. Identify and eliminate ongoing precipitants
4. Counsel on dietary modification (vegetable-based protein, regular meals, avoid protein fasting)
5. Review and eliminate offending medications (sedatives, opioids, proton pump inhibitors - a 2025 meta-analysis [PMID 40812534] shows PPIs significantly increase HE risk in cirrhotic patients and should be used cautiously)

Emerging and Adjunct Therapies

TIPS-Related HE

• TIPS is a common precipitant of HE (worsens portosystemic shunting)
• If medically refractory, shunt reduction or occlusion may be required
• Must weigh against risk of recurrent variceal bleeding

Liver Transplantation

• Liver transplantation (LT) generally reverses HE and is the only definitive therapy
• Indicated in patients with refractory or recurrent HE with appropriate MELD score
• 1- and 3-year survival without LT: 42% and 23%, respectively
• Evaluate for transplant in all patients with overt HE episodes
• Sleisenger and Fordtran's, p.1815; Symptom to Diagnosis

Prognosis

• HE is a poor prognostic indicator: cumulative survival 20-40% at 1 year, 15% at 3 years without transplantation
• Associated with early readmissions and increased 1-year mortality
• Type A (ALF): highest mortality, urgent transplant consideration

Key Points / Clinical Pearls

• Blood ammonia level alone does not diagnose, stage, or predict prognosis of HE - diagnosis is clinical
• Always look for the underlying precipitating cause - treating it is as important as pharmacotherapy
• Avoid benzodiazepines and opioids; if sedation is needed, use low-dose alternatives carefully
• Asterixis (flapping tremor) is present in Grades 1-3 but is not specific to HE
• PPIs increase HE risk in cirrhotic patients and should be reviewed/discontinued if not necessary
• Protein restriction is harmful - maintain adequate protein with source modification